T1	intervention 22 31	nebivolol
T2	condition 40 76	anthracycline-induced cardiomyopathy
T3	total-participants 317 319	45
T4	intervention-participants 420 422	27
T5	control 427 434	placebo
T6	control-participants 438 440	18
T9	outcome 632 659	echocardiographic variables
T11	outcome 1060 1064	LVEF
T14	outcome 1140 1156	NT-pro-BNP level
T10	outcome 711 745	left ventricular (LV) end-systolic
T15	outcome 750 773	end-diastolic diameters
T16	outcome 695 705	At 6-month
T12	cv-cont-mean 1091 1095	57.5
T17	cv-cont-sd 1098 1102	5.6%
T13	iv-cont-mean 1107 1111	63.8
T18	iv-cont-sd 1114 1118	3.9%
T19	cv-cont-mean 813 817	29.7
T20	cv-cont-sd 820 823	3.4
T21	outcome 1128 1138	at 6-month
T22	cv-cont-mean 827 831	33.4
T23	cv-cont-sd 834 839	4.5mm
T24	outcome 806 811	LVESD
T25	outcome 841 846	LVEDD
T26	cv-cont-mean 848 852	47.2
T27	cv-cont-sd 855 858	3.8
T28	cv-cont-mean 862 866	52.0
T29	cv-cont-sd 869 874	4.6mm
T30	outcome 940 945	LVESD
T31	outcome 983 988	LVEDD
T32	iv-cont-mean 947 951	30.4
T33	iv-cont-sd 954 957	3.5
T34	iv-cont-mean 961 965	31.0
T35	iv-cont-sd 968 973	3.6mm
T36	iv-cont-mean 990 994	47.0
T37	iv-cont-sd 997 1000	4.4
T38	iv-cont-mean 1004 1008	47.1
T39	iv-cont-sd 1011 1016	4.0mm
T40	iv-cont-mean 1197 1200	147
T41	iv-cont-sd 1203 1205	57
T42	iv-cont-mean 1209 1212	152
T43	iv-cont-sd 1215 1224	69 pmol/l
T44	cv-cont-mean 1275 1278	144
T45	cv-cont-sd 1281 1283	66
T46	cv-cont-mean 1287 1290	204
T47	cv-cont-sd 1293 1302	73 pmol/l
